NBP
HealthcareNovaBridge Biosciences
$4.37
+$0.10 (+2.34%)
Jan 5, 2026
Price History (1Y)
Analysis
NovaBridge Biosciences is a biotechnology company within the healthcare sector. It has a market capitalization of $503.82M and employs 32 individuals. The company's financial health is characterized by negative profitability metrics, with gross margin, operating margin, and profit margin all at 0.0%. Net income for the trailing twelve months (TTM) is -$26,326,000, while EBITDA is -$34,665,000. The debt-to-equity ratio is 1.26, indicating a relatively high level of debt compared to equity. NovaBridge Biosciences maintains significant cash reserves, with $228.27M on hand. The valuation context of NovaBridge Biosciences is marked by negative P/E and EV/EBITDA ratios (-13.52 and -26.17, respectively), suggesting that the company's stock price may not be reflective of its underlying earnings or value. The 52-week high and low prices are $6.79 and $0.59, respectively, indicating a significant range in recent market performance.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About NovaBridge Biosciences
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
Visit website →Key Statistics
- Market Cap
- $503.82M
- P/E Ratio
- N/A
- 52-Week High
- $6.79
- 52-Week Low
- $0.59
- Avg Volume
- 987.07K
- Beta
- 1.59
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 32